- Home
- OVID vs PROK Comparison
OVID vs PROK Comparison
Compare OVID & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | PROK |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.5M | 296.8M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OVID | PROK |
|---|---|---|
| Price | $2.76 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.60 | ★ $7.40 |
| AVG Volume (30 Days) | ★ 2.5M | 854.2K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,252,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | 1075.00 |
| 52 Week Low | $0.27 | $0.54 |
| 52 Week High | $3.11 | $7.13 |
Technical Indicators
Market Signals| Indicator | OVID | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 45.81 |
| Support Level | $2.56 | $1.73 |
| Resistance Level | $3.11 | $2.58 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 44.83 | 29.07 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.